ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

Home・Aktien・Sanofi SA

Sanofi SA

Geschlossen

BrancheGesundheitswesen

73.96 1.25

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

73.05

Max

74.4

Schlüsselkennzahlen
By Trading Economics
Einkommen	-394M 1.6B
Verkäufe	-12B 11B
KGV Branchendurchschnitt	18.443 51.415
EPS	1.34
Gewinnspanne	14.354
Angestellte	74,846
EBITDA	1.5B 2.7B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+28.85% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-11B 88B
Vorheriger Eröffnungskurs	72.71
Vorheriger Schlusskurs	73.96

Nachrichtenstimmung

By Acuity

40%

60%

127 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

91.3 / 96.1 Unterstützung & Widerstand

Sanofi SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Sanofi SA Prognose

Kursziel

By TipRanks

28.85% Vorteil

12-Monats-Prognose

Durchschnitt 93.702 EUR 28.85%

Hoch 107 EUR

Tief 80 EUR

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Sanofi SA – Dist abgegeben haben.

Technischer Score

By Trading Central

91.3 / 96.1Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Stimmung

By Acuity

127 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.